The first batch of Sputnik vaccine is expected to be produced at SII’s facilities in September. The parties intend to produce over 300 million doses of the vaccine in India per year.
Aikening™ is a new fusion inhibitor. It is the first and only long-acting injectable (as IV infusion QW) available as a dual therapy for treatment-experienced patients with HIV-1 replication.
Sputnik V pioneered the vaccine cocktail approach with two shots. The tests conducted by the Gamaleya Center have demonstrated validity of this approach.
In total, up to 380 million doses of CoronaVac® will be available to both self-financing participants of the Facility as well as those supported by the Gavi COVAX AMC.
There are currently 59 Ph. Eur. texts – covering a variety of topics including vaccines for human use, blood products, antibiotics, radiopharmaceuticals and containers – that refer to the RPT and will be affected.